dc.contributor.author | Zilli, Thomas | |
dc.contributor.author | Achard, Vérane | |
dc.contributor.author | Dal Pra, Alan | |
dc.contributor.author | Schmidt-Hegemann, Nina | |
dc.contributor.author | Jereczek-Fossa, Barbara Alicja | |
dc.contributor.author | Lancia, Andrea | |
dc.contributor.author | Ingrosso, Gianluca | |
dc.contributor.author | Alongi, Filippo | |
dc.contributor.author | Aluwini, Shafak | |
dc.contributor.author | Arcangeli, Stefano | |
dc.contributor.author | Blanchard, Pierre | |
dc.contributor.author | Conde Moreno, Antonio | |
dc.contributor.author | Couñago, Felipe | |
dc.contributor.author | Créhange, Gilles | |
dc.contributor.author | Dirix, Piet | |
dc.contributor.author | Gómez de Iturriaga Piña, Alfonso | |
dc.contributor.author | Guckenberger, Matthias | |
dc.contributor.author | Pasquier, David | |
dc.contributor.author | Sargos, Paul | |
dc.contributor.author | Scorsetti, Marta | |
dc.contributor.author | Belka, Claus | |
dc.date.accessioned | 2022-12-15T16:16:43Z | |
dc.date.available | 2022-12-15T16:16:43Z | |
dc.date.issued | 2022-11 | |
dc.identifier.citation | Radiotherapy and Oncology 176 : 199-207 (2022) | es_ES |
dc.identifier.issn | 0167-8140 | |
dc.identifier.issn | 1879-0887 | |
dc.identifier.uri | http://hdl.handle.net/10810/58843 | |
dc.description.abstract | Background and purpose: Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective and small phase 2 studies and with a large difference across centers. Pending results of ongoing prospec-tive randomized trials, there is a clear need for more consistent treatment indications and radiotherapy practices.Material and methods: A European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee consisting of radiation oncologists' experts in prostate cancer was asked to answer a dedicated question-naire, including 41 questions on the main controversial issues with regard to oligometastatic prostate cancer.Results: The panel achieved consensus on patient selection and routine use of prostate-specific mem-brane antigen positron emission tomography (PSMA PET) imaging as preferred staging and restaging imaging. MDT strategies are recommended in the de novo oligometastatic, oligorecurrent and oligopro-gressive disease setting for nodal, bone and visceral metastases. Radiation therapy doses, volumes and techniques were discussed and commented.Conclusion: These recommendations have the purpose of providing standardization and consensus to optimize the radiotherapy treatment of oligometastatic prostate cancer until mature results of random-ized trials are available. | es_ES |
dc.description.sponsorship | AT would like to acknowledge the support of Cancer Research UK (C33589/A28284 and C7224/A28724) . This project represents independent research supported by the National Institute for Health research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | prostate cancer | es_ES |
dc.subject | radiotherapy | es_ES |
dc.subject | SBRT | es_ES |
dc.subject | elective nodal radiotherapy | es_ES |
dc.subject | oligometastases | es_ES |
dc.subject | ESTRO-ACROP | es_ES |
dc.title | Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2022 The Author(s). Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0167814022044991?via%3Dihub | es_ES |
dc.identifier.doi | 10.1016/j.radonc.2022.10.005 | |
dc.departamentoes | Cirugía, radiología y medicina física | es_ES |
dc.departamentoeu | Kirurgia,erradiologia eta medikuntza fisikoa | es_ES |